Results 171 to 180 of about 304,831 (358)

Selective Estrogen Receptor Modulators and Phytoestrogens: New Therapies for the Postmenopausal Woman [PDF]

, 1999
Lorraine A. Fitzpatrick
openalex   +1 more source

Managing a Long and Winding Road: Estrogen Receptor–Positive Breast Cancer [PDF]

, 2023
Michael Gnant, Nicholas C. Turner, Cristina Hernándo   +2 more
openalex   +1 more source

SIRT5–RAC2 Axis Drives Monocyte‐to‐Macrophage Differentiation to Promote Inflammatory Injury in Premature Ovarian Insufficiency

Advanced Science, EarlyView.
SIRT5 desuccinylates and stabilizes RAC2, activating CSF1R‐dependent signaling to drive monocyte differentiation into M0 macrophages and their polarization toward pro‐inflammatory M1 phenotypes in CTX‐induced premature ovarian insufficiency. Inhibiting the SIRT5‐RAC2 axis attenuates inflammation, reduces granulosa cell apoptosis, and preserves ...
Wenjing TanTai, Yaqi Li, Shengnan Liu, Minjuan Wu, Zhixiao Liu, Junfeng Jiang, Jingjing Chen, Xiaoding Xu, Li Li, Chaoqun Li, Fang Zhao, Ye Liu, Haitao Ni, Tengfei Zhang, Mingjuan Xu, Chaofeng Han   +15 more
wiley   +1 more source

Peering into the Brain's Estrogen Receptors: PET Tracers for Visualization of Nuclear and Extranuclear Estrogen Receptors in Brain Disorders. [PDF]

Biomolecules, 2023
Arjmand S, Bender D, Jakobsen S, Wegener G, Landau AM.   +4 more
europepmc   +1 more source

Polystyrene Microplastics Exposure Aggravates Clear Cell Renal Cell Carcinoma Progression via the NF‐κB and TGF‐β Signaling Pathways

Advanced Science, EarlyView.
This research provides the first comprehensive evidence that PS‐MPs exacerbate ccRCC progression by activating the NF‐κB and TGF‐β pathways. These findings establish PS‐MPs as an environmental risk factor for ccRCC progression and identify the NF‐κB and TGF‐β signaling as potential therapeutic targets to mitigate the adverse effects of ‐PS‐MPs exposure.
Shiqi Ye, Jianfeng Xiang, Siqi Zhou, Qintao Ge, Aihetaimujiang Anwaier, Kun Chang, Gang Wei, Jiahe Lu, Xi Tian, Shuxuan Zhu, Yuchen Jiang, Wei Zhang, Tingting Cai, Moran Xu, Dingwei Ye, Danfeng Xu, Tao Wang, Hailiang Zhang, Wenhao Xu   +18 more
wiley   +1 more source

FIGURE 2 from Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy

, 2023
Mengwu Pan, Valeria Solozobova, Nane C. Kuznik, Nicole Jung, Simone Gräßle, Victor Gourain, Yvonne M. Heneka, Christina A. Cramer von Clausbruch, Olaf Fuhr, Ravi S. N. Munuganti, Danilo Maddalo, Christine Blattner, Antje Neeb, Adam Sharp, Laura Cato, Carsten Weiß, Rinath Jeselsohn, Véronique Orian‐Rousseau, Stefan Bräse, Andrew C.B. Cato   +19 more
openalex   +1 more source

Macrophagic Sclerostin Loop2‐ApoER2 Interaction Required by Sclerostin for Cardiovascular Protective Action

Advanced Science, EarlyView.
Sclerostin loop2‐ApoER2 interaction in macrophages is required by sclerostin to suppress NF‐κB nuclear translocation and phosphorylation, to promote macrophage conversion into anti‐inflammatory subtypes in atherosclerotic aortas, as well as to prevent atherosclerosis and aortic aneurysm development in ApoE−/− mice. Abstract Therapeutic antibody against
Luyao Wang, Xiaohui Tao, Ning Zhang, Xin Yang, Hewen Jiang, Xiaofei Li, Shenghang Wang, Shijian Ding, Sifan Yu, Huarui Zhang, Yihao Zhang, Nanxi Li, Haitian Li, Zhanghao Li, Xiaoxin Wen, Meiheng Sun, Chuanxin Zhong, Jin Liu, Yuanyuan Yu, Xianghang Luo, Tao Zhang, Shu Zhang, Péter Ferdinandy, Yu Huang, Daqing Ma, Aiping Lu, Baoting Zhang, Ge Zhang   +27 more
wiley   +1 more source

Figure 4 from The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER⁺ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

, 2023
Mandy Lawson, Natalie Cureton, Susana R�os, Azadeh Cheraghchi-Bashi, Jelena Urosevic, Sophie D’Arcy, Oona Delpuech, Michelle DuPont, David I. Fisher, Eric T. Gangl, Hilary Lewis, Dawn Trueman, Neha Wali, Stuart C. Williamson, Jennifer Moss, Élodie Montaudon, Héloïse Derrien, Elisabetta Marangoni, Ricardo J. Miragaia, Sladjana Gagrica, Pablo Morentin Gutierrez, Thomas A. Moss, Gareth Maglennon, Daniel Sutton, Radosław Polański, Alan Rosen, Jonathan Cairns, Pei Zhang, Mònica Sánchez-Guixé, Violeta Serra, Susan E. Critchlow, James S. Scott, Justin P.O. Lindemann, Simon T. Barry, Teresa Klinowska, Christopher J. Morrow, Larissa S. Carnevalli   +36 more
openalex   +1 more source

CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target

Advanced Science, EarlyView.
This review conceptualizes CD147 as a fundamental “Energy‐Structure Coupler,” physically bridging metabolic flux (via MCTs) with morphogenetic plasticity (via integrins/MMPs) to drive cancer, infection, and autoimmunity. Addressing the “specificity paradox” that limits current translation, the authors chart a strategic roadmap—spanning logic‐gated ...
Xiang‐Min Yang, Huijie Bian, Zhi‐Nan Chen   +2 more
wiley   +1 more source

Long‐term prognosis is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status

BJS (British Journal of Surgery), EarlyView., 2020
This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund, F. Celebioglu, T. Hatschek, J. Frisell, J. de Boniface   +4 more
wiley   +1 more source